Key result
Although nearly 800 NF-kappaB inhibitors have been described without reaching clinical trials, ACE inhibitors and AT1 blockers beneficially inhibit this pathway in hypertensive and renal injury.
Design
Review
Authors
Loading...
May support NF-κB inhibition trials in hypertension and CKD; leaves open efficacy in randomized studies.
Angiotensin II-induced cardiovascular and renal injury is mediated in part by NF-kappaB signaling, highlighting a potential mechanistic target for treating hypertensive and renal diseases.
Li et al. (2008) conducted a review in Hypertensive and renal diseases. NF-kappaB inhibitors, ACE inhibitors, and AT1 blockers was evaluated. Although nearly 800 NF-kappaB inhibitors have been described without reaching clinical trials, ACE inhibitors and AT1 blockers beneficially inhibit this pathway in hypertensive and renal injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: